NeuroPace, Inc. (NASDAQ:NPCE) Stock Has Consensus Target Price of $19.33

by · The Cerbat Gem

NeuroPace, Inc. (NASDAQ:NPCE – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $19.33.

NPCE has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of NeuroPace in a research note on Wednesday, July 29th. Guggenheim reiterated a “neutral” rating on shares of NeuroPace in a research report on Wednesday, July 29th. Mizuho started coverage on NeuroPace in a report on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a report on Monday, September 21st. Finally, KeyCorp began coverage on NeuroPace in a research report on Thursday, September 17th. They issued an “overweight” rating and a $18.00 price objective for the company.

Get Our Latest Research Report on NPCE

Institutional Investors Weigh In On NeuroPace

Several institutional investors and hedge funds have recently added to or reduced their stakes in NPCE. BlackRock Inc. purchased a new position in NeuroPace during the second quarter valued at $39,369,000. GSA Capital Partners LLP purchased a new stake in shares of NeuroPace during the second quarter worth about $1,836,000. Deutsche Bank AG acquired a new position in shares of NeuroPace during the 2nd quarter worth about $14,919,000. First Light Asset Management LLC raised its position in shares of NeuroPace by 16.3% during the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after purchasing an additional 401,201 shares during the last quarter. Finally, Man Group plc purchased a new position in NeuroPace in the 2nd quarter valued at about $1,336,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Stock Performance

Shares of NASDAQ NPCE opened at $14.06 on Wednesday. The company has a market capitalization of $482.54 million, a PE ratio of -24.67 and a beta of 1.94. The company has a debt-to-equity ratio of 4.97, a quick ratio of 3.91 and a current ratio of 4.94. The company’s fifty day moving average price is $14.44 and its 200 day moving average price is $15.26. NeuroPace has a 1 year low of $9.22 and a 1 year high of $19.60.

NeuroPace (NASDAQ:NPCE – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. The company had revenue of $22.83 million during the quarter, compared to analysts’ expectations of $22.61 million. NeuroPace had a negative net margin of 19.34% and a negative return on equity of 105.64%. On average, research analysts predict that NeuroPace will post -0.67 earnings per share for the current year.

NeuroPace Company Profile

(Get Free Report)

NeuroPace, Inc is a medical technology company focused on developing therapies for people with drug-resistant epilepsy. The company’s principal product is the RNS System, an implantable responsive neurostimulation device designed to monitor brain activity, identify patterns associated with seizures, and deliver targeted electrical stimulation intended to reduce seizure frequency.

The RNS System includes an implanted neurostimulator, leads placed near seizure-producing areas of the brain, and external software and programming tools used by clinicians.

See Also